A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.
Also called NCT02358096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT02358096 -
2014-002349-23
-
- Other papers using this trial's data
- Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02358096. Randomized; triple masking; primary purpose treatment. Start 2015-03-17 (actual); primary completion 2016-10-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Acronym
- ALBUM
- Condition
- Chronic Kidney Disease
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- ASP8232
- Intervention (Drug)
- Placebo
- Lead sponsor
- Astellas Pharma Europe B.V.
Record details
- Record id
cardio:ct-nct02358096- Content hash
fe0d8b6e14aa407c569f35426714b3eb0f059255437e4219487baa1b2c172acd